73 Covid cases with delta variant identified on Guam
Updated: Dec 21, 2021
By Pacific Island Times News Staff
The Department of Public Health and Social Services on Monday received 73 new results from virus samples collected on Guam between Oct. 1 and 16, which have undergone genome sequencing by the U.S. Centers for Disease Control and Prevention.
DPHSS received the twelfth set of results from the CDC. All 73 samples received were identified as the delta variant of concern (VOC). The breakdown is as follows: Delta (VOC) Two AY.103; 52 AY 25; 16 AY.3 and Three AY.4
To date, 438 SARS-CoV-2 virus samples have been submitted to the CDC for genome sequencing and identified a total of 237 Covid-19 cases infected with variants.
DPHSS previously reported variants from results from the CDC and identified the following:
89 cases identified with the B.1.1.7 Alpha variant
14 cases identified with the B.1.429 Epsilon variant
four cases identified with the B.1.351 Beta variant
129 cases identified with the Delta variant and its sublineages
one case identified with the P.1 Gamma variant
The department reported four new cases of COVID-19 from 85 specimens analyzed on Dec. 19. An additional 14 cases were also reported today as a result of complete analysis and case submissions from other clinics for preliminary Covid-19 test results reported Dec. 18 and 19.
Official case counts for the past weekend results are as follows:
11 of 811 test positive for Covid-19 (three cases previously reported on Dec. 18. Two cases were identified through contact tracing.
Nine (9) of 442 test positive for Covid-19 (three cases previously reported on Dec. 19). One case was identified through contact tracing.
To date, there have been a total of 19,390 officially reported cases, 270 deaths, 216 cases in active isolation, and 18,904 not in active isolation. The CAR Score is 0.8.
As of Dec. 19, a total of 128,280 of Guam’s eligible population (residents 5 years and older) is fully vaccinated. This total includes 12,538 residents 12 – 17 years old. 4,362 residents 5 – 11 years old received their first dose of the Pfizer-BioNTech two-dose series. 2,001 residents 5 – 11 years old have completed their two-dose series.
An additional 167 residents received their booster shots and a total of 36,221 booster shots have been administered to eligible residents since Sept. 29.